4-butyrolactone has been researched along with caffeine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hirata, M; Ishizaka, Y; Minemoto, Y; Nakagama, H; Ohtsubo, M; Sasagawa, T; Shimura, M; Uchida, S; Yamashita, K | 1 |
| Cao, YX; He, JY; He, LC; Xu, CB; Zhang, W | 1 |
2 other study(ies) available for 4-butyrolactone and caffeine
| Article | Year |
|---|---|
Loss of p53 induces M-phase retardation following G2 DNA damage checkpoint abrogation.
Topics: 4-Butyrolactone; Antineoplastic Agents; Aphidicolin; Blotting, Western; Caffeine; CDC2 Protein Kinase; CDC2-CDC28 Kinases; Cell Cycle; Cyclin B; Cyclin B1; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; DNA Damage; Dose-Response Relationship, Drug; Doxorubicin; Enzyme Inhibitors; Flow Cytometry; G2 Phase; Humans; Mitosis; Oncogene Proteins, Viral; Phenotype; Protein Kinases; Protein Serine-Threonine Kinases; Repressor Proteins; S Phase; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2003 |
Ligustilide induces vasodilatation via inhibiting voltage dependent calcium channel and receptor-mediated Ca2+ influx and release.
Topics: 4-Butyrolactone; Animals; Caffeine; Calcium; Calcium Channel Blockers; Calcium Channels; Calcium Chloride; Calcium Signaling; Dose-Response Relationship, Drug; In Vitro Techniques; Male; Mesenteric Artery, Superior; Myography; Norepinephrine; Potassium Chloride; Rats; Ryanodine Receptor Calcium Release Channel; Serotonin; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 2006 |